Home » FDA Approves Depomed's Proquin XR for Urinary Tract Infections
FDA Approves Depomed's Proquin XR for Urinary Tract Infections
Depomed has received FDA approval for Proquin XR, a once-daily, extended-release formulation of ciprofloxacin HCl for the treatment of uncomplicated urinary tract infections (UTIs).
The market for ciprofloxacin is estimated at $1.5 billion worldwide in the U.S., with prescriptions for uncomplicated UTI's representing a significant portion of usage, Depomed said.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
07May
-
14May
-
30May